tetano
Editor, Senior Moderator
Viral Immunol. 2011 Oct;24(5):369-74.
Antiviral Potential of Exogenous Human Omega Interferon to Inhibit Pandemic 2009 A (H1N1) Influenza Virus.
Xu C, Song X, Fu L, Dong D, Wu S, Li G, Yi S, Yu T, Yu R, Hou L, Chen W.
Source
State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology , Beijing, China .
Abstract
Abstract The pandemic 2009 H1N1 influenza virus broke out in North America and spread rapidly throughout the world. The type I interferon (IFN) response represents one of the first lines of defense against influenza virus infections. In this study, the protective potential of human exogenous IFN-ω against pandemic 2009 A (H1N1) influenza virus was assessed both in vitro and in guinea pigs. The viral loads of pandemic 2009 A (H1N1) influenza virus strains A/California/04/2009 and A/Beijing/501/2009 were reduced by up to 5000-fold in Caco-2 cells by the addition of human IFN-ω. With daily intranasal treatment with human IFN-ω the viral load of pandemic 2009 A (H1N1) influenza virus strain A/California/04/2009 decreased by 1000-fold in lung tissues of guinea pigs. These results provide strong support for the application of human IFN-ω pretreatment to human influenza control.
PMID:
22004136
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22004136
Antiviral Potential of Exogenous Human Omega Interferon to Inhibit Pandemic 2009 A (H1N1) Influenza Virus.
Xu C, Song X, Fu L, Dong D, Wu S, Li G, Yi S, Yu T, Yu R, Hou L, Chen W.
Source
State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology , Beijing, China .
Abstract
Abstract The pandemic 2009 H1N1 influenza virus broke out in North America and spread rapidly throughout the world. The type I interferon (IFN) response represents one of the first lines of defense against influenza virus infections. In this study, the protective potential of human exogenous IFN-ω against pandemic 2009 A (H1N1) influenza virus was assessed both in vitro and in guinea pigs. The viral loads of pandemic 2009 A (H1N1) influenza virus strains A/California/04/2009 and A/Beijing/501/2009 were reduced by up to 5000-fold in Caco-2 cells by the addition of human IFN-ω. With daily intranasal treatment with human IFN-ω the viral load of pandemic 2009 A (H1N1) influenza virus strain A/California/04/2009 decreased by 1000-fold in lung tissues of guinea pigs. These results provide strong support for the application of human IFN-ω pretreatment to human influenza control.
PMID:
22004136
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22004136